Ji-Su Chen

TL;DR: The combination therapy of rhTNFR-Fc plus MTX was an effective therapy for moderate-to-severe plaque psoriasis with an acceptable safety and tolerability profile, indicating that it was feasible and well tolerated for patients.

TL;DR: Through global gene expression analysis in PBMC of psoriasis patient and subsequent co-expression module based pathway analyses, a group of functionally coherent and differentially expressed genes (DEGs) and related pathways are identified, which has not only provided new biological insight about the molecular mechanism of anti-TNF- α treatment, but also identified several genes whose expression profiles can be used as potential biomarkers for anti-tumor necrosis factor alpha treatment response in Psoriasis.

TL;DR: It is concluded that 2 equilibria influence the efficacy of ustekinumab against psoriasis: first, because of the dual roles of p35 in Psoriasis pathogenesis, homeostasis occurs between p35 and p40 expression levels, and the second balance lies between the upregulation of p40 mRNA levels and the ability of Ustek inumab to neutralize the function of the elevated p40 protein.

TL;DR: The PK of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis was comparable to findings in global populations and an acceptable safety profile was observed.